-
Sector Analysis
Pancreatic Cancer in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, China, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Pancreatic cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases. Key Highlights - Report deliverables include an Excel-based forecast model - Forecasts...
-
Sector Analysis
HER2-Negative Breast Cancer Epidemiology Analysis and Forecast to 2034
Breast cancer is a malignant tumor originating within the breast tissue. The most common type of breast cancer is invasive breast cancer, which originates from the milk ducts and invades the surrounding breast tissue (Cancer Research UK, 2023a). As it progresses, the cancer can metastasize to other parts of the body via the bloodstream and lymphatic system (American Cancer Society, 2022). According to the World Health Organization (WHO), breast cancer was the most common diagnosed cancer in women in 157...
-
Sector Analysis
Head and Neck Squamous Cell Carcinoma Epidemiology Analysis and Forecast to 2034
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth (International Statistical Classification of Diseases and Related Health Problems 10th Revision [ICD-10] code = C00–C06); the salivary glands (ICD-10 code = C07–C08); the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx (ICD-10 code = C09–C14); the nose, sinuses, and related structures (ICD-10 code = C30–C31), and...
-
Sector Analysis
Current Trends in Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC) – Market Drivers and Challenges
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases There are currently ten actionable genomic alterations (AGAs) that are addressed by targeted therapy agents across multiple lines of therapy. Patients who did not undergo genetic testing or tested negative for AGAs, receive immunotherapy agents depending on their PD-L1 status. Chemotherapy works as salvage therapy for late-line recurrent/relapsed patients. - Targeted therapy in NSCLC is a highly competitive...
-
Sector Analysis
B-Cell Non-Hodgkin's Lymphoma Epidemiology Analysis and Forecast to 2033
Non-Hodgkin’s lymphoma (NHL) represents a group of cancers that develop in the lymphatic system. Individuals with NHL experience uncontrolled malignant white blood cells, rendering the immune system incapable of effectively fighting off infections. Among all malignant lymphomas, the 90% are composed of NHL, making it among the most prevalent hematological adult cancers (Ekströ Smedby et al., 2008). NHL is segmented by its histology into B-cell, T-cell, and natural killer lymphocyte lymphoma, with B-cell lymphoma constituting 80─85% of the three subtypes....
-
Product Insights
Squamous Non-Small Cell Lung Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Squamous Non-Small Cell Lung Cancer - Global Clinical Trials Review, 2025" provides an overview of Squamous Non-Small Cell Lung Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Squamous Non-Small Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Sector Analysis
Myelodysplastic Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics. - GlobalData epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. - MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies. - The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase...
-
Product Insights
Acute Lymphocytic Leukemia (ALL) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Global Clinical Trials Review, 2025" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Product Insights
Bladder Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Bladder Cancer - Global Clinical Trials Review, 2025" provides an overview of Bladder Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Bladder Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Prostate Cancer Epidemiology Analysis and Forecast to 2033
Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.4 million men were diagnosed with prostate cancer in 2020 (Wang et al., 2022). In the US, prostate cancer is the most common cancer in men after skin cancer, and it is the third most common cause of cancer death in men (Siegel et al., 2020). Approximately one in seven American men are diagnosed with...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.